Supernus Pharmaceuticals to Report Q4 and Full Year 2024 Results

By Bobby Samwell • Wednesday, February 12 15:20 • Permanent Link

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) has announced that it will be reporting its financial and business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. The company has stated that it will host a conference call to discuss these results on the same day at 4:30 p.m. ET.

The press release highlighted that Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Additionally, Supernus Pharmaceuticals is developing a broad range of novel CNS product candidates, including new potential treatments for epilepsy, depression, and other CNS disorders.

Investors and stakeholders can access a live webcast of the conference call in the events & presentations section of the company’s investor relations website. A replay of the webcast will also be available on the company's investor relations website for 60 days following the live call.

This announcement comes as the company prepares to present its financial and business results, providing an opportunity for investors and analysts to gain insights into Supernus Pharmaceuticals' performance and strategic direction. Today the company's shares have moved 1.7% to a price of $39.29. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.